Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. .. Read more With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence, and performance gaps exist in the optimal management of metastatic castration-sensitive prostate cancer (mCSPC). The CE program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies. This activity is in collaboration with the Association of Community Cancer Centers (ACCC) and will award continuing education hours for physicians, pharmacists, and nurses.
- Share your Experience